BSD Medical announces outcomes from BSD-2000 hyperthermia system research on pancreatic cancer BSD Medical Company . The scholarly research, Gemcitabine and cisplatin coupled with regional hyperthermia as second-line treatment in individuals with gemcitabine-refractory advanced pancreatic malignancy , reported the results of a retrospective analysis of 23 individuals with advanced or metastatic pancreatic cancer who had relapsed following first-line chemotherapy treatment. The experts, Tschoep-Lechner, et al., reported that hyperthermia, shipped using the BSD-2000, coupled with gemcitabine and cisplatin led to low toxicity and high feasibility, actually in these scholarly research patients who had an extremely negative prognosis no standard treatment options.Pre-cancer, if I had a poor week I would just take it easy dieting and drop two pounds. Lesser-known signs of breast cancer women should view forResearchers at Johns Hopkins Cancer Center decided the issue needed more study when they noticed a development in excess weight gain among breast tumor survivors and wanted to understand the reason. Little research existed about fat gain in breast cancers survivors compared to women who never really had tumor. They carried out a two-part study over four years, funded by the Breast Cancer Research Basis and the National Institutes of Health, with more than 600 women defined as coming to higher risk for breast cancer due to family history. Participants included 303 women treated and diagnosed for breasts cancer and 307 who also were at risk however, not diagnosed.